Lupin is currently trading at Rs. 2110.60, up by 20.95 points or 1.00 % from its previous closing of Rs. 2089.65 on the BSE.
The scrip opened at Rs. 2090.75 and has touched a high and low of Rs. 2127.40 and Rs. 2090.75 respectively. So far 14387 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2127.40 and Rs. 2046.05 respectively. The current market cap of the company is Rs. 96411.96 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its injectable facility in Nagpur, India, with a satisfactory Voluntary Action Indicated (VAI) classification. The EIR was issued following an inspection of the facility from September 8 to September 16, 2025.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
